Dianthus Therapeutics Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Dianthus Therapeutics's estimated annual revenue is currently $5.3M per year.(i)
  • Dianthus Therapeutics's estimated revenue per employee is $77,500

Employee Data

  • Dianthus Therapeutics has 68 Employees.(i)
  • Dianthus Therapeutics grew their employee count by 66% last year.

Dianthus Therapeutics's People

NameTitleEmail/Phone
1
VPReveal Email/Phone
2
Chief Accounting Officer (CAO)Reveal Email/Phone
3
SVP, Head Regulatory AffairsReveal Email/Phone
4
VP, Antibody Discovery & EngineeringReveal Email/Phone
5
SVP, General Counsel and SecretaryReveal Email/Phone
6
VP, Discovery ResearchReveal Email/Phone
7
SVP, Head Clinical Development OperationsReveal Email/Phone
8
VP OperationsReveal Email/Phone
9
VP, Program, Alliance, and Non-clinical DevelopmentReveal Email/Phone
10
Head Program, Alliance & Nonclinical DevelopmentReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is Dianthus Therapeutics?

Dianthus is a biotechnology company dedicated to designing and delivering the next generation of best-in-class monoclonal antibodies with improved selectivity and potency. Led by a multidisciplinary team of seasoned biotech entrepreneurs and scientists, we are pioneering selective antibodies of validated and emerging complement targets to allow people with rare and severe autoimmune diseases live healthier lives to their fullest potential.

keywords:N/A

N/A

Total Funding

68

Number of Employees

$5.3M

Revenue (est)

66%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$12.9M68-11%N/A
#2
$13.5M6813%N/A
#3
$13.7M68-14%N/A
#4
N/A68-11%N/A
#5
$13.7M6826%N/A